Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
Paul Welsh, Claire Welsh, Carlos A Celis-Morales, Rosemary Brown, Lyn D Ferguson, Patrick B Mark, James Lewsey, Stuart R Gray, Donald M Lyall, Jason MR Gill, Jill P Pell, James A de Lemos, Peter Willeit, Naveed Sattar
doi: https://doi.org/10.1101/2020.03.30.20043554
Paul Welsh
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Claire Welsh
bInstitute for Ageing, Newcastle University
Carlos A Celis-Morales
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Rosemary Brown
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Lyn D Ferguson
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Patrick B Mark
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
James Lewsey
cInstitute of Health and Wellbeing, University of Glasgow
Stuart R Gray
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Donald M Lyall
cInstitute of Health and Wellbeing, University of Glasgow
Jason MR Gill
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Jill P Pell
cInstitute of Health and Wellbeing, University of Glasgow
James A de Lemos
dDivision of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center
Peter Willeit
eDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria; Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Naveed Sattar
aInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Posted April 01, 2020.
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
Paul Welsh, Claire Welsh, Carlos A Celis-Morales, Rosemary Brown, Lyn D Ferguson, Patrick B Mark, James Lewsey, Stuart R Gray, Donald M Lyall, Jason MR Gill, Jill P Pell, James A de Lemos, Peter Willeit, Naveed Sattar
medRxiv 2020.03.30.20043554; doi: https://doi.org/10.1101/2020.03.30.20043554
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
Paul Welsh, Claire Welsh, Carlos A Celis-Morales, Rosemary Brown, Lyn D Ferguson, Patrick B Mark, James Lewsey, Stuart R Gray, Donald M Lyall, Jason MR Gill, Jill P Pell, James A de Lemos, Peter Willeit, Naveed Sattar
medRxiv 2020.03.30.20043554; doi: https://doi.org/10.1101/2020.03.30.20043554
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2300)
- Dermatology (205)
- Emergency Medicine (372)
- Epidemiology (11631)
- Forensic Medicine (10)
- Gastroenterology (685)
- Genetic and Genomic Medicine (3636)
- Geriatric Medicine (342)
- Health Economics (624)
- Health Informatics (2335)
- Health Policy (921)
- Hematology (336)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3393)
- Nursing (193)
- Nutrition (512)
- Oncology (1783)
- Ophthalmology (527)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6031)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (144)